Most recent update: Friday, October 20, 2017 - 14:37

Bariatric News - Cookies & privacy policy

You are here

Stretta cases in Brazil

First Stretta cases for GERD treatment performed in Brazil

Stretta is a transoral, non-surgical intervention that uses low power radiofrequency (RF) energy to remodel the muscle between the stomach and oesophagus.

Mederi Therapeutics has announced that the first cases of Stretta Therapy, a non-surgical treatment for gastroesophageal reflux disease (GERD), have been performed in Brazil. Dr Manoel Galvao Neto and Dr Eduardo Grecco, hosted Stretta training and performed the first cases at Fundacao do ABC Hospital in Sao Paolo, welcoming physicians from all over Brazil to learn about Stretta. In total, 45 new physicians were trained in the Stretta procedure.

"This is a proven solution for patients who have GERD symptoms despite medications and want to avoid surgery, Stretta is an ideal option between medications and surgery. Our team is excited about this innovative technology,” said Dr Neto.

Stretta is a transoral, non-surgical intervention that uses low power radiofrequency (RF) energy to remodel the muscle between the stomach and oesophagus. Studies demonstrate that Stretta resolves reflux symptoms, improves quality of life, reduces or eliminates medications, and decreases acid exposure in patients with chronic GERD.

Figure 1: Stretta therapy delivers low power, low temperature radiofrequency energy to remodel the valve known as the lower oesophageal sphincter (LES) at the junction of the oesophagus and the stomach. (Credit: PRNewsFoto/Mederi Therapeutics Inc.)

According to a 2014 study, roughly 20 percent of Brazilians suffer from chronic GERD, with symptoms consisting of heartburn, regurgitation, and even chronic cough. Obesity is on the rise in Brazil with some estimates predicting more than half of the population of Latin America will be overweight or obese by 2030. Studies show that obese patients have a much higher incidence of GERD than the general population.

"Stretta is also cost-effective compared to long-term PPI use or anti-reflux surgery,” added dr Grecco. “Being able to offer a procedure that is clinically effective, and has an economic advantage is important here in Brazil."

Bariatric surgery is also on the rise in Brazil, with about 86,000 procedures per year being performed in 2013 vs. 4,000 in 2003. Many bariatric patients, particularly those who have undergone a sleeve gastrectomy, report chronic GERD symptoms following surgery, despite weight loss.

"We are very pleased with the excitement around Stretta in Brazil. Stretta is experiencing dramatic growth worldwide, this is driven by key benefits of safety and effectiveness, as well as the versatility and lower cost of Stretta compared to other GERD treatments," stated Mederi CEO Bob Knarr. "Stretta is a unique technology that reduces symptoms of GERD by thickening the muscle between the stomach and the oesophagus, improving the barrier to reflux. We look forward to great success in Brazil, where we have an excellent distribution partner, Endoaccess.”

"Stretta is positioned to help many kinds of chronic GERD patients, including those who have incomplete relief from medications or have recurring GERD after bariatric or anti-reflux surgery,” said Thiago Regis, principal of Endoaccess. “It is especially important for the patient with GERD after bariatric surgery. In this patient, Stretta offers an important option because it is non-surgical, delivered endoscopically, and does not alter the anatomy or require an implant. Surgeons and Gastroenterologists throughout Brazil are eager to offer Stretta to their patients."

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox.